Investors lose their appetite for the obesity trade
In a few short years, excitement about groundbreaking anti-obesity drugs made Novo Nordisk Europe’s most highly valued company and Eli...
In a few short years, excitement about groundbreaking anti-obesity drugs made Novo Nordisk Europe’s most highly valued company and Eli...